> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Relypsa sNDA for Drug-Drug Interactions
- URL: https://www.fdaweb.com/relypsa-snda-for-drug-drug-interactions/
- Published: 2016-05-25T12:00:00.000Z
- Updated: 2026-09-14T21:05:22.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5135767

Relypsa has submitted a supplemental NDA requesting label changes for Veltassa (patiromer) for oral suspension based on results of 12 Phase 1 drug-drug interaction studies in healthy volunteers. Veltassa was approved in 2015 for treating hyperkalemia.

 The drug-drug interaction program submitted as part of Veltassa’s original NDA included 28 *in vitro* drug-drug interaction tests, according to Relypsa. Fourteen showed binding with Veltassa and 14 showed no binding. Of those that that did show binding, 12 were selected for further testing in healthy volunteers, the company says. “These Phase 1 studies showed that when Veltassa was administered at the same time as the drugs being tested, there was no clinically meaningful reduction in absorption for nine of the 12 drugs,” it says. “Three drugs showed reduced absorption when they were co-administered with Veltassa, however, when dosing of Veltassa and these drugs was separated by three hours, no reduction in absorption was observed.”